Precipio Inc

Precipio Inc (PRPO) News & Events

$28.850

-0.433 (-1.50%)At close

PRPO News

PRPO Events

5/14 17:10

Precipio CEO Highlights Continued Growth in Business Fundamentals

"I think this quarter is a good example of how to properly assess non-commercial fluctuations in our business," said Ilan Danieli, CEO of Precipio. "While revenue is flat, that is largely a function of timing. The underlying business fundamentals continue to grow, in particular the product pipeline that has been generated by our newly hired commercial team."

3/10 09:10

Precipio Launches New Assay for Chronic Myeloid Leukemia

Precipio has announced the publication in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio's new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia, CML. Ilan Danieli, CEO of Precipio, expanded on these findings. "Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all four clinically important variants of BCR::ABL1 (isoforms). Precipio is first to apply the International Scale to create a novel assay quantifying all four variants, setting a new standard for monitoring patients with CML. Now, for the first time, clinicians can comprehensively monitor disease progression."

2/25 09:40

Ilan Danieli: Company Value Tripled in 2025

"Becoming an EBITDA and cash-flow positive business has a very important impact on how we manage the business. It allows us to now invest in growth projects that consider a longer-term perspective for the Company, rather than a constant focus on short-term cash burn considerations." said Ilan Danieli, CEO. "2025 was a great year for us, one where the business performed well, and shareholders saw their value triple. We are confident in our ability to continue to create this value."

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started